AgomAb Therapeutics (AGMB) FDA Approvals $5.44 -0.18 (-3.20%) Closing price 03:59 PM EasternExtended Trading$5.43 -0.01 (-0.18%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC FilingsShort Interest AgomAb Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by AgomAb Therapeutics (AGMB). Over the past two years, AgomAb Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Ontunisertib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Ontunisertib FDA Regulatory Timeline and Events Ontunisertib is a drug developed by AgomAb Therapeutics for the following indication: Fibrostenosing Crohn’s Disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dose Update - October 13,2026Dose Update Phase 2bDrug: OntunisertibAnnounced Date: October 13, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.AI SummaryAgomab Therapeutics NV announced that the first patient has received treatment in NOV-ERA, a global Phase 2b study of ontunisertib for adults with symptomatic fibrostenosing Crohn’s disease (FSCD). The trial is expected to enroll about 320 patients. It is randomized, double-blind, and placebo-controlled, meaning participants and researchers will not know who receives the drug or placebo during the study. Participants will receive one of three twice-daily doses of ontunisertib—100, 200, or 400 mg—or placebo for 52 weeks. The main goal is to measure how many patients’ narrowed bowel passages can be passed with an endoscope at Week 24. Researchers will also assess safety, imaging results, symptoms, quality of life, and FSCD-related events such as surgery. Agomab says the study will help guide the choice of outcomes for later trials. The company views ontunisertib as a potential targeted treatment for fibrosis, a cause of bowel narrowing. The drug is investigational; its safety and effectiveness have not been established.Read AnnouncementData Presentation - October 8,2026Data Presentation Phase 2aDrug: OntunisertibAnnounced Date: October 8, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced that OLE data of the Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in Barcelona, Spain.AI SummaryAgomab Therapeutics NV said data from the open-label extension (OLE) of its Phase 2a STENOVA study will be presented in an oral session at UEG Week 2026, held October 17–20 in Barcelona, Spain. The study examined long-term treatment with ontunisertib in people with symptomatic fibrostenosing Crohn’s disease, a form of Crohn’s disease that causes narrowing of the bowel. Participants received 200 mg twice daily for up to 48 additional weeks after the initial 12-week study period. Of those eligible to continue, 49 joined the extension, and 37 completed it. The OLE assessed long-term safety and drug levels, and explored disease progression and clinical events. The presentation will include objective imaging assessments. Agomab said the findings support moving ahead with its planned global Phase 2b NOV-ERA study. The company will also host a scientific symposium on how inflammation and fibrosis contribute to bowel damage and potential treatment approaches. Ontunisertib remains investigational; its safety and effectiveness have not been established.Read AnnouncementPositive Results - October 1,2026Positive Results Drug: OntunisertibAnnounced Date: October 1, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD, a severe manifestation of Crohn's disease characterized by progressive bowel fibrosis and intestinal strictures.AI SummaryAgomab Therapeutics reported positive results from the 48-week open-label extension of its Phase 2a STENOVA trial of ontunisertib in people with fibrostenosing Crohn’s disease, a severe form marked by bowel scarring and narrowing. Of eligible patients, 49 (94%) entered the extension, and 37 completed it. Participants received ontunisertib twice daily alongside standard care, for up to 60 weeks of treatment overall. The treatment showed a generally favorable safety and tolerability profile. Five serious adverse events occurred in four patients; all were considered unrelated or unlikely to be related to the drug. Researchers also reported low drug levels in the blood, consistent with its gut-focused design. Only one Crohn’s-related procedure—a balloon dilation—was reported, with no surgeries. This represented a 3% annualized event rate. Imaging suggested that bowel strictures remained stable, while symptoms and disease activity stayed low. At Week 48, 97% of evaluable patients were in clinical remission based on a disease activity score. Agomab plans to begin the global Phase 2b NOV-ERA trial in the coming months. Ontunisertib remains investigational; its safety and effectiveness have not been established.Read AnnouncementProvided Update - June 23,2026Provided Update Phase 2bDrug: OntunisertibAnnounced Date: June 23, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).AI SummaryAgomab Therapeutics NV has announced the design of its upcoming Phase 2b NOV-ERA study of ontunisertib, an investigational oral, GI-restricted inhibitor of ALK5 for the potential treatment of fibrostenosing Crohn’s disease (FSCD). The study is planned to test three doses of ontunisertib—400 mg, 200 mg, and 100 mg—against placebo in a 1:1:1:1 randomization, with twice-daily dosing. The trial will include a 6-week screening period, a 52-week treatment period, and a 2-week follow-up. Its main goal is to measure the proportion of patients who achieve endoscopic passability of the ileal index stricture at Week 24, a novel endpoint meant to help show whether the treatment can ease bowel narrowing. Agomab said the study is intended to help identify endpoints for later registrational trials. First patient dosing is expected in the second half of 2026, and the company notes that ontunisertib is still experimental and has not been proven safe or effective.Read Announcement AgomAb Therapeutics FDA Events - Frequently Asked Questions Has AgomAb Therapeutics received FDA approval? As of now, AgomAb Therapeutics (AGMB) has not received any FDA approvals for its therapy in the last two years. What drugs has AgomAb Therapeutics submitted to the FDA? In the past two years, AgomAb Therapeutics (AGMB) has reported FDA regulatory activity for Ontunisertib. What is the most recent FDA event for AgomAb Therapeutics? The most recent FDA-related event for AgomAb Therapeutics occurred on October 13, 2026, involving Ontunisertib. The update was categorized as "Dose Update," with the company reporting: "Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD." What conditions do AgomAb Therapeutics' current drugs treat? Currently, AgomAb Therapeutics has one therapy (Ontunisertib) targeting the following condition: Fibrostenosing Crohn’s Disease. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Belite Bio FDA EventsErasca FDA EventsGilead Sciences FDA EventsNuCana FDA EventsUnited Therapeutics FDA EventsAdagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies MoonLake Immunotherapeutics FDA Events Savara FDA Events Jade Biosciences FDA Events Oric Pharmaceuticals FDA Events Corvus Pharmaceuticals FDA Events Pharming Group FDA Events Odyssey Therapeutics FDA Events MeiraGTx FDA Events Monte Rosa Therapeutics FDA Events Aktis Oncology FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:AGMB last updated on 10/14/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgomAb Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Share AgomAb Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dose Update - October 13,2026Dose Update Phase 2bDrug: OntunisertibAnnounced Date: October 13, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.AI SummaryAgomab Therapeutics NV announced that the first patient has received treatment in NOV-ERA, a global Phase 2b study of ontunisertib for adults with symptomatic fibrostenosing Crohn’s disease (FSCD). The trial is expected to enroll about 320 patients. It is randomized, double-blind, and placebo-controlled, meaning participants and researchers will not know who receives the drug or placebo during the study. Participants will receive one of three twice-daily doses of ontunisertib—100, 200, or 400 mg—or placebo for 52 weeks. The main goal is to measure how many patients’ narrowed bowel passages can be passed with an endoscope at Week 24. Researchers will also assess safety, imaging results, symptoms, quality of life, and FSCD-related events such as surgery. Agomab says the study will help guide the choice of outcomes for later trials. The company views ontunisertib as a potential targeted treatment for fibrosis, a cause of bowel narrowing. The drug is investigational; its safety and effectiveness have not been established.Read Announcement
Data Presentation - October 8,2026Data Presentation Phase 2aDrug: OntunisertibAnnounced Date: October 8, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced that OLE data of the Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in Barcelona, Spain.AI SummaryAgomab Therapeutics NV said data from the open-label extension (OLE) of its Phase 2a STENOVA study will be presented in an oral session at UEG Week 2026, held October 17–20 in Barcelona, Spain. The study examined long-term treatment with ontunisertib in people with symptomatic fibrostenosing Crohn’s disease, a form of Crohn’s disease that causes narrowing of the bowel. Participants received 200 mg twice daily for up to 48 additional weeks after the initial 12-week study period. Of those eligible to continue, 49 joined the extension, and 37 completed it. The OLE assessed long-term safety and drug levels, and explored disease progression and clinical events. The presentation will include objective imaging assessments. Agomab said the findings support moving ahead with its planned global Phase 2b NOV-ERA study. The company will also host a scientific symposium on how inflammation and fibrosis contribute to bowel damage and potential treatment approaches. Ontunisertib remains investigational; its safety and effectiveness have not been established.Read Announcement
Positive Results - October 1,2026Positive Results Drug: OntunisertibAnnounced Date: October 1, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD, a severe manifestation of Crohn's disease characterized by progressive bowel fibrosis and intestinal strictures.AI SummaryAgomab Therapeutics reported positive results from the 48-week open-label extension of its Phase 2a STENOVA trial of ontunisertib in people with fibrostenosing Crohn’s disease, a severe form marked by bowel scarring and narrowing. Of eligible patients, 49 (94%) entered the extension, and 37 completed it. Participants received ontunisertib twice daily alongside standard care, for up to 60 weeks of treatment overall. The treatment showed a generally favorable safety and tolerability profile. Five serious adverse events occurred in four patients; all were considered unrelated or unlikely to be related to the drug. Researchers also reported low drug levels in the blood, consistent with its gut-focused design. Only one Crohn’s-related procedure—a balloon dilation—was reported, with no surgeries. This represented a 3% annualized event rate. Imaging suggested that bowel strictures remained stable, while symptoms and disease activity stayed low. At Week 48, 97% of evaluable patients were in clinical remission based on a disease activity score. Agomab plans to begin the global Phase 2b NOV-ERA trial in the coming months. Ontunisertib remains investigational; its safety and effectiveness have not been established.Read Announcement
Provided Update - June 23,2026Provided Update Phase 2bDrug: OntunisertibAnnounced Date: June 23, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).AI SummaryAgomab Therapeutics NV has announced the design of its upcoming Phase 2b NOV-ERA study of ontunisertib, an investigational oral, GI-restricted inhibitor of ALK5 for the potential treatment of fibrostenosing Crohn’s disease (FSCD). The study is planned to test three doses of ontunisertib—400 mg, 200 mg, and 100 mg—against placebo in a 1:1:1:1 randomization, with twice-daily dosing. The trial will include a 6-week screening period, a 52-week treatment period, and a 2-week follow-up. Its main goal is to measure the proportion of patients who achieve endoscopic passability of the ileal index stricture at Week 24, a novel endpoint meant to help show whether the treatment can ease bowel narrowing. Agomab said the study is intended to help identify endpoints for later registrational trials. First patient dosing is expected in the second half of 2026, and the company notes that ontunisertib is still experimental and has not been proven safe or effective.Read Announcement